Epigenomics and Predictive Biosciences have extended their licensing agreement for the prostate cancer biomarker GSTP1, originally signed in April 2009.
Under the terms of the original agreement, Predictive Biosciences had obtained rights to develop a prostate cancer test incorporating DNA methylation biomarker and an option to license GSTP1 for commercialisation of this test as a laboratory service in the US.
Based on continued progress in developing the test, Predictive Biosciences has now executed this option, triggering an undisclosed one-time license fee to Epigenomics.
Epigenomics will also be entitled to royalties on future sales generated with Predictive Biosciences’ prostate cancer test, which is still in development.
Epigenomics CEO Geert Nygaard said that they are delighted that Predictive Biosciences will be using their biomarker to develop a test to improve the diagnostic follow-up of patients with high PSA.
Predictive Biosciences president and CEO Peter Klemm said that the biomarker will provide a valuable contribution to the portfolio of tests they are commercialising in the field of urologic oncology.
Berlin-based Epigenomics is a molecular diagnostics company with a focus on the development of novel products for cancer.
Predictive Biosciences is a developer of novel molecular diagnostic cancer assays and an urology-focused provider of anatomic pathology laboratory products and services.